Repatha Cost in Illinois 2026: What You'll Actually Pay

What Is the List Price of Repatha in Illinois in 2026?

Amgen's wholesale acquisition cost for Repatha sits at approximately $580 per month in 2026, whether you fill the prescription in Chicago, Springfield, or Rockford. That figure reflects both the 140 mg every-two-weeks pen and the 420 mg once-monthly SureClick autoinjector. The cash-pay retail price at Illinois pharmacies closely tracks the WAC because few independent discount arrangements exist for branded biologics at the dispensing level. Patients without insurance or savings-card access therefore face the full $580 monthly burden unless they pursue alternative sourcing.

The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia and for patients with homozygous familial hypercholesterolemia [1]. The approved label specifies 140 mg subcutaneously every two weeks or 420 mg once monthly as therapeutically equivalent regimens [1]. Because Repatha is a biologic, no FDA-approved generic is available. That biologic status is a primary driver of its sustained high list price relative to statin therapy, which costs as little as $4 per month at many Illinois pharmacies [2].

Cardiovascular benefit data justify the cost for high-risk patients. The FOURIER trial (N=27,564) demonstrated that adding evolocumab to optimized statin therapy reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years [3]. LDL-C fell by 59% from a median baseline of 92 mg/dL [3].

How Does Illinois Medicaid Cover Repatha?

Illinois Medicaid (administered through managed care organizations under the HealthChoice Illinois program) covers Repatha with prior authorization for two distinct clinical scenarios: heterozygous or homozygous familial hypercholesterolemia, and established atherosclerotic cardiovascular disease (ASCVD) in patients who have not achieved guideline-recommended LDL targets on maximally tolerated statin therapy [4].

The Illinois Department of Healthcare and Family Services (HFS) aligns its PA criteria broadly with the ACC/AHA 2018 cholesterol guideline, which recommends PCSK9 inhibitor therapy for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [5]. That guideline states: "In very high-risk patients, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable." [5]

Prescribers must submit documentation confirming: a qualifying diagnosis (ASCVD or FH), a recent fasting lipid panel showing LDL-C above threshold, evidence that the patient is on maximally tolerated statin therapy, and a trial of ezetimibe (unless contraindicated). Medicaid managed care plans in Illinois, including Meridian Health Plan, Molina Healthcare of Illinois, and Blue Cross Community Health Plans, generally adopt these same criteria but may impose additional step-therapy requirements. Checking the specific plan formulary before submitting a PA request saves time [4].

Once approved, Illinois Medicaid patients pay $0 to a nominal co-pay for Repatha at in-network pharmacies. The approval period is typically 12 months, requiring annual renewal with updated lipid labs [4].

Which Commercial Insurance Plans Cover Repatha in Illinois?

Most major commercial plans operating in Illinois, including Blue Cross Blue Shield of Illinois, Aetna, Cigna, UnitedHealthcare, and Humana, place Repatha on Tier 4 or Tier 5 specialty formulary tiers. At those tiers, out-of-pocket costs before the Amgen savings card can range from $150 to $600 per month depending on plan design [6].

The 2022 Inflation Reduction Act capped out-of-pocket drug costs for Medicare Part D enrollees at $2,000 per year starting in 2025, which meaningfully reduces the annual burden for Illinois Medicare beneficiaries using Repatha [7]. For patients on Medicare Part D, Repatha is covered under most plans' specialty tier, and the new $2,000 annual cap means that after reaching the threshold, the patient pays $0 for the remainder of the plan year [7].

Commercial plan PA requirements typically mirror Medicaid: documented ASCVD or FH, LDL-C above threshold, and documented statin intolerance or inadequate response. Step therapy requiring a documented statin trial of at least 90 days is common. Illinois law under 215 ILCS 5/356z.22 requires insurers to offer a step-therapy exception process, so patients who qualify clinically but are stuck in step therapy have a legal pathway to appeal [8].

The ACC/AHA Pooled Cohort Equations tool, available through the American College of Cardiology, can help quantify 10-year ASCVD risk to support PA documentation [9].

How Does the Amgen Savings Card Work in Illinois?

The Amgen Repatha PCSK9 Savings Program is the single most impactful cost-reduction tool for commercially insured Illinois patients. Eligible patients, defined as those with commercial or private insurance who are not covered by a government plan such as Medicare, Medicaid, or TRICARE, may pay as little as $0 per month [10].

Enrollment is completed online at amgen.com or through a prescribing provider's office. The card is accepted at most major Illinois retail pharmacies including CVS, Walgreens, Jewel-Osco pharmacy, Costco Pharmacy, and Walmart Pharmacy. The savings card covers the gap between the plan's cost-sharing requirement and the eligible out-of-pocket cap, up to a defined annual maximum benefit [10].

Patients should verify two things before relying on the savings card: first, that their specific insurance plan does not prohibit copay accumulator programs (some BCBS IL plans have adopted accumulator adjusters that prevent savings-card payments from counting toward the plan deductible); second, that the pharmacy has the card on file before dispensing. Illinois passed no state law banning accumulator adjusters as of 2025, so this remains a risk [11].

For patients whose plans use an accumulator adjuster, the effective savings-card benefit may be reduced after the plan deductible is met. In that scenario, working with a specialty pharmacy that has a patient assistance navigator, such as CVS Specialty or Walgreens Specialty, can identify additional bridge options [11].

Is Compounded Evolocumab Legal in Illinois?

Yes. Compounded evolocumab prepared by a state-licensed 503A compounding pharmacy is legal in Illinois, subject to important regulatory conditions [12]. A 503A pharmacy compounds on a patient-specific, prescription-by-prescription basis under state pharmacy board oversight and must use bulk drug substances that are either USP-grade or obtained from FDA-registered suppliers [12].

The Illinois Department of Professional Regulation (IDFPR) licenses compounding pharmacies operating within the state. Prescribers and patients should confirm that any 503A pharmacy they use holds an active Illinois license or, if located out of state, holds a valid non-resident pharmacy permit issued by IDFPR [13].

One substantive legal note: evolocumab is not currently on the FDA's 503A bulk drug substances list (the "nominated substances" list maintained under 21 CFR Part 1). This means the compounded product is prepared from bulk drug substance under the general 503A framework rather than under an affirmative FDA designation. The FDA has not taken enforcement action against individual 503A compounding of evolocumab as of 2025, but prescribers should document clinical rationale for choosing the compounded form over the commercially available product [12] [14].

Cash price for compounded evolocumab at 503A pharmacies in Illinois varies by pharmacy and formulation. Some telehealth-affiliated compounding pharmacies quote prices below the Amgen WAC, making this the lowest cash-pay option for uninsured or underinsured Illinois patients. Patients should request a certificate of analysis for each lot to verify concentration and sterility [13].

Can a Telehealth Provider in Illinois Prescribe Repatha?

Illinois permits telehealth prescribing of non-controlled medications including Repatha under the Illinois Telehealth Act (410 ILCS 151), provided the prescriber holds an active Illinois medical license and establishes a valid patient-provider relationship [15]. A valid relationship requires a clinical evaluation sufficient to make a diagnosis, which for Repatha means reviewing a fasting lipid panel, a cardiovascular risk assessment, and prior medication history.

HealthRX connects Illinois patients with board-certified cardiologists and internal medicine physicians who can evaluate lipid panels remotely, determine eligibility under ACC/AHA 2018 criteria, complete prior authorization paperwork for Illinois Medicaid or commercial plans, and send prescriptions to the patient's preferred Illinois pharmacy or a 503A compounding pharmacy [5] [9].

Telehealth prescribing does not bypass the insurance PA process. The prescribing clinician must still submit the same documentation required for an in-office prescription. The advantage of a telehealth visit is speed: appointments are typically available within 48 hours, and PA submission can begin the same day [15].

What Is the Cheapest Way to Get Repatha in Illinois?

Cost depends on insurance status.

For commercially insured patients: enroll in the Amgen savings card to reduce cost-sharing to $0 or near-$0 per month. This remains the lowest-cost path for patients with private insurance [10].

For Illinois Medicaid patients: obtain prior authorization using the ACC/AHA 2018 criteria framework. Approved Medicaid patients pay $0 to minimal co-pay [4] [5].

For Medicare Part D patients: under the 2025 out-of-pocket cap, maximum annual drug spending is $2,000. Many plans place Repatha in the catastrophic tier once the cap is reached, reducing per-fill cost to $0 for the rest of the calendar year [7].

For uninsured or underinsured cash-pay patients: compounded evolocumab from a licensed Illinois 503A pharmacy is typically the lowest-cost option. Patients should obtain a written prescription specifying concentration and volume, confirm the pharmacy's IDFPR license, and request a sterility and potency certificate of analysis [12] [13].

The Amgen Repatha PCSK9 Patient Assistance Program (not the savings card, a separate program) provides free Repatha to uninsured patients who meet income criteria, generally at or below 600% of the federal poverty level [10]. Illinois residents can apply directly through Amgen's patient support program, Amgen Assist 360, reachable at the contact information on amgen.com [10].

GoodRx and similar coupon platforms rarely reduce Repatha's price below the WAC for branded biologics. Do not rely on GoodRx as a primary cost-reduction strategy for this drug [6].

Clinical Evidence Supporting Use: Why the Price May Be Worth It

The evidence base for evolocumab in high-risk patients goes beyond LDL reduction. FOURIER (N=27,564) showed a 20% relative reduction in the hard endpoint of cardiovascular death, MI, or stroke when comparing the third year of therapy to the first, suggesting that longer treatment duration compounds the benefit [3]. The number needed to treat to prevent one MI, stroke, or cardiovascular death over 2.2 years was approximately 67 [3].

The GLAGOV trial (N=968) used intravascular ultrasound and demonstrated that evolocumab produced statistically significant regression of coronary atherosclerosis at 76 weeks, with mean percent atheroma volume decreasing by 0.95% in the evolocumab group versus an increase of 0.05% in the placebo group (P<0.001) [16]. Plaque regression occurred in 64.3% of evolocumab patients versus 47.3% of placebo patients [16].

For patients with familial hypercholesterolemia, the TESLA trial (N=49) showed a 30.9% reduction in LDL-C from baseline in homozygous FH patients, a population where statin therapy alone typically yields inadequate control [17]. The FDA granted approval for homozygous FH patients on the basis of this evidence [1].

The 2022 ACC Expert Consensus Decision Pathway on PCSK9 inhibitor use states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe, PCSK9 inhibitor therapy is recommended." [18] This language directly supports Medicaid and commercial PA documentation in Illinois.

Safety data from FOURIER showed no statistically significant increase in serious adverse events, neurocognitive effects, or new-onset diabetes with evolocumab versus placebo over 2.2 years [3]. The FDA-approved label lists injection-site reactions as the most common adverse event, occurring in approximately 2.1% of patients [1].

Illinois-Specific Cost Decision Framework for Prescribers

Prescribers seeing lipid patients in Illinois can apply a four-step pathway before the first prescription is sent:

Step 1. Confirm clinical eligibility. The patient must have established ASCVD or FH, an LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe (or documented statin intolerance), and a 10-year ASCVD risk calculated using the Pooled Cohort Equations [5] [9].

Step 2. Check insurance status. For commercial plans, identify the formulary tier and whether the plan uses an accumulator adjuster. For Illinois Medicaid managed care, identify the specific MCO and its PA form. For Medicare Part D, confirm the plan's specialty tier cost-sharing and the patient's current out-of-pocket spending for the year [4] [7].

Step 3. Enroll or direct enrollment in the appropriate savings program. Commercial patients go to the Amgen savings card. Uninsured patients below 600% FPL apply to Amgen Assist 360. Cash-pay patients above income thresholds get a referral to a licensed 503A pharmacy [10].

Step 4. Submit PA documentation in a single packet: diagnosis codes (Z00.00 or applicable ICD-10), recent lipid panel within 90 days, statin and ezetimibe trial documentation, and the ACC/AHA risk classification [5] [18]. Incomplete packets are the single most common reason for PA denial and delay.

This four-step approach reduces the time from prescription to first dose, which in clinical practice is the primary barrier to PCSK9 inhibitor uptake in Illinois and nationally [18].

Monitoring and Follow-Up After Starting Repatha in Illinois

After the first injection, a fasting lipid panel at four to eight weeks confirms the LDL-C response. Target LDL-C for very high-risk ASCVD patients is below 55 mg/dL per the 2019 European Society of Cardiology guideline, or below 70 mg/dL per the 2018 ACC/AHA guideline [5] [19]. Illinois providers typically use the ACC/AHA threshold for insurance documentation purposes and the ESC threshold as an aspirational clinical goal.

If LDL-C does not fall by at least 50% from baseline, adherence should be assessed before adjusting dose. Patients self-administering subcutaneous injections at home may benefit from a brief telehealth check-in at the 4-week mark to review injection technique and address any injection-site discomfort [15].

Liver function testing and creatine kinase monitoring are not required on a routine basis with evolocumab, unlike with high-intensity statins, because the mechanism of action does not involve hepatic enzyme induction [1]. Annual lipid panels are sufficient for monitoring once a stable LDL-C response is established [5].

Illinois Medicaid requires annual PA renewal with updated lipid labs. Scheduling the follow-up lipid panel 30 to 60 days before the PA expiration date ensures continuous coverage without a coverage gap [4].